User: Guest  Login
More Searchfields
Simple search
Title:

Metabolic profiling links cardiovascular risk and vascular end organ damage.

Document type:
Article; Journal Article; Research Support, Non-U.S. Gov't
Author(s):
Streese, Lukas; Springer, Anna Maria; Deiseroth, Arne; Carrard, Justin; Infanger, Denis; Schmaderer, Christoph; Schmidt-Trucksäss, Arno; Madl, Tobias; Hanssen, Henner
Abstract:
BACKGROUND AND AIMS: An untargeted metabolomics approach allows for a better understanding and identification of new candidate metabolites involved in the etiology of vascular disease. We aimed to investigate the associations of cardiovascular (CV) risk factors with the metabolic fingerprint and macro- and microvascular health in an untargeted metabolomic approach in predefined CV risk groups of aged individuals. METHODS: The metabolic fingerprint and the macro- and microvascular health from 155 well-characterized aged (50-80 years) individuals, based on the EXAMIN AGE study, were analysed. Nuclear magnetic resonance spectroscopy was used to analyse the metabolic fingerprint. Carotid-femoral pulse wave velocity and retinal vessel diameters were assessed to quantify macro- and microvascular health. RESULTS: The metabolic fingerprint became more heterogeneous with an increasing number of risk factors. There was strong evidence for higher levels of glutamine [estimate (95% CI): -14.54 (-17.81 to -11.27), p < 0.001], glycine [-5.84 (-7.88 to -3.79), p < 0.001], histidine [-0.73 (-0.96 to -0.50), p < 0.001], and acetate [-1.68 (-2.91 to -0.46), p = 0.007] to be associated with a lower CV risk profile. Tryptophan, however, was positively associated with higher CV risk [0.31 (0.06-0.56), p = 0.015]. The combination of a priori defined CV risk factors explained up to 45.4% of the metabolic variation. The metabolic fingerprint explained 20% of macro- and 23% of microvascular variation. CONCLUSIONS: Metabolic profiling has the potential to improve CV risk stratification by identifying new underlying metabolic pathways associated with atherosclerotic disease development, from cardiovascular risk to metabolites, to vascular end organ damage.
Journal title abbreviation:
Atherosclerosis
Year:
2021
Journal volume:
331
Pages contribution:
45-53
Fulltext / DOI:
doi:10.1016/j.atherosclerosis.2021.07.005
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/34344526
Print-ISSN:
0021-9150
TUM Institution:
Fachgebiet Nephrologie (Prof. Heemann)
 BibTeX